Deutsche Bank Ag\ Cel Sci Corp Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$2.58 - $4.99 $53,800 - $104,056	-20,853 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$3.93 - $7.7 $28,759 - $56,348	-7,318 Reduced 25.98%	20,853 $82,000
Q4 2021 Feb 11, 2022	BUY	$7.1 - $12.82 $8,207 - $14,819	1,156 Added 4.28%	28,171 $200,000
Q3 2021 Nov 04, 2021	SELL	$7.64 - $12.49 $2,994 - $4,896	-392 Reduced 1.43%	27,015 $297,000
Q2 2021 Aug 11, 2021	SELL	$8.68 - $27.49 $4,643 - $14,707	-535 Reduced 1.91%	27,407 $238,000
Q1 2021 May 13, 2021	SELL	$12.0 - $27.64 $24,768 - $57,048	-2,064 Reduced 6.88%	27,942 $424,000
Q4 2020 Feb 16, 2021	BUY	$11.05 - $16.62 $76,874 - $115,625	6,957 Added 30.18%	30,006 $350,000
Q3 2020 Nov 12, 2020	BUY	$11.69 - $14.54 $18,470 - $22,973	1,580 Added 7.36%	23,049 $294,000
Q2 2020 Aug 13, 2020	BUY	$9.75 - $17.6 $45,981 - $83,001	4,716 Added 28.15%	21,469 $321,000
Q1 2020 May 14, 2020	SELL	$7.54 - $17.05 $88,414 - $199,928	-11,726 Reduced 41.17%	16,753 $193,000
Q4 2019 Feb 14, 2020	BUY	$6.71 - $9.55 $133,810 - $190,446	19,942 Added 233.59%	28,479 $259,000
Q3 2019 Nov 14, 2019	SELL	$6.0 - $9.6 $77,550 - $124,080	-12,925 Reduced 60.22%	8,537 $74,000
Q2 2019 Aug 14, 2019	SELL	$3.77 - $8.67 $501,930 - $1.15 Million	-133,138 Reduced 86.12%	21,462 $178,000
Q1 2019 May 15, 2019	BUY	$2.58 - $3.54 $398,865 - $547,280	154,599 Added 0.0%	154,600 $547,000
Q3 2018 Nov 14, 2018	SELL	$0.83 - $4.16 $165 - $827	-199 Reduced 99.5%	1 $0
Q2 2018 Apr 21, 2020	SELL	$0.92 - $3.5 $0 - $3	-1 Reduced 0.5%	200 $0
Q2 2018 Aug 14, 2018	BUY	$0.92 - $3.5 $184 - $700	200 Added 20000.0%	201 $0
Q3 2017 Nov 14, 2017	BUY	$1.59 - $3.0 $1 - $3	1	1 $0

Others Institutions Holding CVM

# of Institutions

Shares Held

5.94M

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $16.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account